Literature DB >> 15661540

Cellular abnormalities of blood vessels as targets in cancer.

Peter Baluk1, Hiroya Hashizume, Donald M McDonald.   

Abstract

Tumor blood vessels have multiple structural and functional abnormalities. They are unusually dynamic, and naturally undergo sprouting, proliferation, remodeling or regression. The vessels are irregularly shaped, tortuous, and lack the normal hierarchical arrangement of arterioles, capillaries and venules. Endothelial cells in tumors have abnormalities in gene expression, require growth factors for survival and have defective barrier function to plasma proteins. Pericytes on tumor vessels are also abnormal. Aberrant endothelial cells and pericytes generate defective basement membrane. Angiogenesis inhibitors can stop the growth of tumor vessels, prune existing vessels and normalize surviving vessels. Loss of endothelial cells is not necessarily accompanied by simultaneous loss of pericytes and surrounding basement membrane, which together can then provide a scaffold for regrowth of tumor vessels. Rapid vascular regrowth reflects the ongoing drive for angiogenesis and bizarre microenvironment in tumors that promote vascular abnormalities and thereby create therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15661540     DOI: 10.1016/j.gde.2004.12.005

Source DB:  PubMed          Journal:  Curr Opin Genet Dev        ISSN: 0959-437X            Impact factor:   5.578


  241 in total

Review 1.  Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization.

Authors:  Amber N Stratman; George E Davis
Journal:  Microsc Microanal       Date:  2011-12-14       Impact factor: 4.127

Review 2.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

3.  Role of bone marrow-derived cells in angiogenesis: focus on macrophages and pericytes.

Authors:  Yanping Ding; Nan Song; Yongzhang Luo
Journal:  Cancer Microenviron       Date:  2012-04-20

Review 4.  Targeting angiogenesis in gynecologic cancers.

Authors:  Behrouz Zand; Robert L Coleman; Anil K Sood
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

5.  Tumor vascular microenvironment determines responsiveness to photodynamic therapy.

Authors:  Amanda L Maas; Shirron L Carter; E Paul Wileyto; Joann Miller; Min Yuan; Guoqiang Yu; Amy C Durham; Theresa M Busch
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

Review 6.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

Review 7.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 8.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

Review 9.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

10.  Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Authors:  Chunhua Lu; Mian M K Shahzad; Myrthala Moreno-Smith; Yvonne G Lin; Nicholas B Jennings; Julie K Allen; Charles N Landen; Lingegowda S Mangala; Guillermo N Armaiz-Pena; Rosemarie Schmandt; Alpa M Nick; Rebecca L Stone; Robert B Jaffe; Robert L Coleman; Anil K Sood
Journal:  Cancer Biol Ther       Date:  2010-02-16       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.